Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K951632
    Date Cleared
    1997-03-06

    (699 days)

    Product Code
    Regulation Number
    864.5220
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    ORTHO-MUNE OK-COMBO CONTROL IGG2A-FITC/IGG2A-PE MONOCLONAL ANTIBODY (MURINE)

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Ortho-mune OK-COMBO Control is intended for use as negative control for immunophenotying of human lymphocytes in whole blood by flow cytometry using Orthomune OK-COMBO immunophenotyping reagents. Ortho-mune OK-COMBO immunophenotyping reagents are blends of two purified monoclonal antibodies conjugated to fluorescein isothiocyanate and phycoerythrin, respectively. The negative control is used to check for nonspecific background staining and to set the negative/positive rergions of the fluorescent cytograms.

    Device Description

    Ortho-mune OK-COMBO Control IgG2-FITC/IgG2-PE Monoclonal Antibody (Murine) is a blend of murine monoclonal antibodies, not specific for human cellular antigens, conjugated to the fluorochromes, fluorescein isothiocyanate (FITC) and phycoerythrin (PE), respectively.

    AI/ML Overview

    Here's an analysis of the provided text, outlining the acceptance criteria and study details for the Ortho-mune™ OK-COMBO Control IgG2-FITC/IgG2-PE Monoclonal Antibody (Murine):

    Device: Ortho-mune™ OK-COMBO Control IgG2-FITC/IgG2-PE Monoclonal Antibody (Murine)
    Intended Use: Negative control for immunophenotyping of human lymphocytes in whole blood by flow cytometry using Ortho-mune OK-COMBO immunophenotyping reagents. Used to check for non-specific background staining and to set negative/positive regions of fluorescent cytograms.

    1. Table of Acceptance Criteria and Reported Device Performance

    The document doesn't explicitly state "acceptance criteria" with numerical thresholds for performance. Instead, the study aims to demonstrate substantial equivalence to a predicate device (Simultest™ IMK Plus Reagent B-Control) and acceptable reproducibility and linearity. Therefore, the "acceptance criteria" are implied by the comparative performance and good internal consistency.

    Performance MetricAcceptance Criteria (Implied by Equivalence/Acceptability)Reported Device Performance (Ortho-mune OK-COMBO Control)
    Equivalence to Predicate Device
    Mean % Events in Positive Region (Normal Donors)Similar mean % and range as the predicate (Simultest IMK Control), with small ΔMean and CI. (e.g., ΔMean approaching 0, CI covering 0).FITC: Mean 0.32% (SD 0.50, Range 0-1.32). ΔMean vs. predicate: 0.07 (CI 0.07).
    PE: Mean 0.38% (SD 0.78, Range 0-1.95). ΔMean vs. predicate: 0.13 (CI 0.12).
    Mean % Events in Positive Region (AIDS/ARC Patients)Similar mean % and range as the predicate (Simultest IMK Control), with small ΔMean and CI.FITC: Mean 0.43% (SD 0.34, Range 0-1.10). ΔMean vs. predicate: 0.11 (CI 0.08).
    PE: Mean 0.44% (SD 0.56, Range 0-1.55). ΔMean vs. predicate: 0.13 (CI 0.12).
    Reproducibility
    Within Laboratory Reproducibility (CV)Low coefficient of variation (CV) across different sample types, suggesting consistent results within a laboratory. (No specific threshold given, but values generally below ~1% are good in flow cytometry).CD19 Depleted: 0.403%. CD4 Depleted: 0.151%. CD8 Depleted: 0.084%. Normal: 0.215%. (These are "All Sites" CVs based on aggregated variance; individual site CVs are lower).
    Between Laboratory Reproducibility (CV)Low coefficient of variation (CV) across different laboratories, suggesting consistent results between labs. (No specific threshold given, but generally
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1